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FORMULASI DAN PANCIRIAN KRIM-NANO BERASAKAN ESTER MINYAK 
SAWIT UNTUK PENYAMPAIAN PIROKSIKAM SECARA TOPIKAL: 
PELPASAN IN VITRO DAN KESAN ANTI-INFLAMOTORI DAN ANALGESIK 
IN VIVO 
 
ABSTRAK 
 
 
Sejak beberapa tahun kebelakangan ini, terdapat peningkatan dalam penggunaan 
sistem pembara topikal yang depat membantu penelapan drug melalui kulit. Drug yang 
terlibat biasanya yang mempunyai masalah bila diambil secara oral, contohnya: mudah 
terhidrolisis dalam saluran gastrousus, biokereroleban yang rendah atau menyebabkan 
tindak balas mudarat. Satu daripada drug tersebut ialah piroxicam. Ia merupakan anti-
inflamasi, tik dan analgesik yang amat efektif, tetapi menyebabkan pendarahan dan ulser 
gastrousus. Satu daripada sistem pembira ini yang berpotensi menelapkan drug secara 
trans-dermal ialah krim-nano, iaitu suatu emulsi separa pepejal ber titisan 20-200 nm. 
Tujuan utama kajian ini dijalankan adalah untuk memformulasikan suatu krim-nano 
novel yang mengandungi piroxicam untuk penyampaian topikal dan menggunakan 
minyak ester sawit (POEs) suatu minyak sawit terderivertis yang baru sebagai fasa 
minyak. 
Dalam kajian awal, rajah-rajah fasa pseudoternari bagi campuran air, POEs dan 
surfaktan bukan ion pelbagai nilai HLB telah hasilkan dan beberapa formula krim-nano 
telah dipilih. Keterlarutan dan pekali pembahagian piroxicam dan kesan drug ini 
terhadap cirik formulasi formula yang dipilih pag dikaji. Kestabilan pada suhu yang 
xvii 
 
berbeza dan sifat formulasi yang lain termasuk perlakuan reologi, potensi zeta, saiz 
titisan dan ciri-ciri struktur formulasi juga dikaji.   
Berdasarkan kajian awal yang dilakukan pada beberapa formulasi yang dipilih, suatu 
formula dengan komposisi asas 25:37:38 POEs;  fasa akues: campuran surfaktan (80% 
Tween 80: 20% Span 20 HLB 13.72) telah diguna untuk menghasilkan beberapa krim-
nano dengan menggunakan penampan fosfat masing-masing pada  pH 4, pH 6 dan  pH 
7.4 sebagai fasa luaran.  Kemampuan formulasi tersebut untuk melepaskan piroxicam 
menembusi membran selulosa asetat dan ketebalan kulit tikus dinilai secara in vitro 
dengan menggunakan sel pembauran Frantz (Frantz diffusion cell). Formulasi E15 dan 
E16 dikenal pasti sebagai berpotensi dan kesan-kesan farmakodinamik dinilai serta 
dibandingkan dengan satu sediaan yang terdapat di pasaran.  Kesan anti-inflamasi diukur 
dengan menggunakan kaedah edema tapak kaki belakang yang diindus oleh karagenan 
dimana isipadu edema diukur berdasarkan ketebalan tapak kaki. Aktiviti analgesis 
ukurkan sebagai respons ambang kesakitan.  
Sebagai kesimpulan, krim-nano yang dirumus melalui penggunaan POEs sebagai 
fasa minyak dan penampan fosfat pH 6 dan 7.4 sebagai fasa luarnya serta  mengandungi 
0.5% piroxicam, didapati mempunyai cirri-ciri reologi, saiz titisan serta kestabilan yang 
sesuai.  Krim-nano (pH 7.4) E16 menunjukkan perpindahan drug secara in vitro melalui  
membran selulosa asetat dan ketebalan kulit tikus  yang lebih baik jika dibandingkan 
dengan krim-nano (pH 6) dan sediaan rujukan yang diperolehi dipasaran. Hal ini 
mungkin disebabkan nilai fluksnya yang lebih tinggi. Krim-nano (pH 7.4) E16 
menunjukkan aktiviti anti-inflamasi dan analgesis terbaik di kalangan sediaan-sediaan  
yang diuji.  
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FORMULATION AND CHARACTERIZATION OF PALM OIL ESTERS 
BASED NANO-CREAM FOR TOPICAL DELIVERY OF PIROXICAM: STUDY 
OF IN VITRO RELEASE AND IN VIVO ANTI-INFLAMMATORY AND 
ANALGESIC EFFECTS 
 
ABSTRACT 
 
 
During recent years, there has been increased interest in the use of topical vehicle 
systems that could assist drug permeation through the skin. The drugs of interest usually 
those causing or having problems when given orally, e.g., easily hydrolyzed in the 
gastro-intestinal tract, poor bioavailability or to cause adverse reactions. One such drug 
is piroxicam, a highly effective anti-inflammatory, anti-pyretic and analgesic but causes 
gastro-intestinal ulcers and bleeding.  One of the most promising vehicle systems for 
trans-dermal permeation of drugs is a nano-cream, a semisolid emulsion with droplet 
size of 20-200 nm. The main purpose of this study is to formulate a novel nano-cream 
containing piroxicam for topical delivery and to use palm oil esters (POEs) a new 
derrivetised palm oil as the oil phase. In the initial study, pseudoternary phase diagrams 
of water, POEs and non-ionic surfactant mixture of several HLB values were 
constructed and several promising nano-cream formulae were selected. The stability 
under different temperatures and other properties of the formulations including the 
rheological behaviour, zeta potential, droplet size and structural characteristics of the 
formulation and Solubility and partition coeffecient of piroxicam were studied.  
xix 
 
Based on the initial studies conducted on selected several formulae, a formula with 
25:37:38 basic composition of palm oil esters: aqueous phase: surfactant mixture (80% 
Tween 80: 20% Span 20 HLB 13.72) was used to prepare several nano-creams using 
phosphate buffer pH 4, pH 6 and pH 7.4 respectively as the external phase. The abilities 
of these formulae to deliver piroxicam through cellulose acetate membrane and full 
thickness rat skin were assessed in vitro using Frantz diffusion cell. E15 and E16 were 
identified as the promising formulae and their pharmacodynamic effects were evaluated 
and compared with a preparation available in market. Anti- inflammatory effect was 
measured by using carragennan-induced hind paw edema method where the edema 
volume was measured in term of paw thickness. The analgesic activity was measured as 
the pain threshold response. In conclusion, the 0.5% nano-creams formulated by using 
the POEs as the oil phase and phosphate buffer pH 6 and 7.4 as external phase were 
found to have suitable rheological, droplet size and stability properties. Nano-cream (pH 
7.4) E16 had shown a better in vitro transfer through cellulose acetate membrane and 
full thickness rat skin as compared to nano-cream (pH 6) and a product available in 
market. This could be due to the higher flux calculated. The E16 nano-cream (pH 7.4) 
showed the best anti-inflammatory and analgesic activities among the preparations 
tested.  
1 
 
CHAPTER ONE 
INTRODUCTION 
 
1.1 Introduction 
Since the last decades, the treatment of illness has been accomplished by 
administrating drugs to humans via various means which are namely oral, sublingual, 
rectal, parental, inhalation and topical delivery, etc. Topical delivery can be defined as 
the application of formulation containing a drug to the skin to directly treat cutaneous 
disorders (e.g. acne) or to the cutaneous manifestations of a general disease (e.g. 
psoriasis) with the intention of producing pharmacological or other effects of the drug to 
the surface of the skin, within the skin or to tissue under the skin. 
The topical application of medicines was introduced in the ancient history. 
Antibiotics and hormones topical delivery were administered in the 1940s. Generally, 
any agent whether toxic or beneficial to the human body, is susceptible to be absorbed if 
it comes into contact with the skin. Topical delivery systems may include drug 
administration to the skin for local effect such as steroid for dermatitis, nicotine patches 
for systemic effects, cosmetics for surface effect and NSAIDs for effects on deeper 
tissues like inflamed muscle. 
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1.2 Advantages and Disadvantages of Topical Drug Delivery Systems 
Topical delivery systems include various dosage forms for example: cream, 
ointment and gel. These systems have numerous benefits over other conventional dosage 
forms as listed in 1.2.1. As for other dosage forms, these topical systems also have 
several disadvantages (Walters and Roberts, 2002). Their disadvantages are listed in 
1.2.2. 
 
1.2.1 Advantages of Topical Drug Delivery Systems 
These dosage forms: 
•  Bypass the first pass metabolism which is a potential hindrance with the use of 
oral administration of drugs. 
• Promote a patient’s compliance as they are convenient and easy to apply. 
• Are able to avoid the risks and inconveniences of intravenous injections. 
• Can forgo varied conditions of absorption in the gastrointestinal tract GIT, like 
pH changes, the presence of enzymes, gastric emptying time etc. 
• Can avoid the fluctuation in drug plasma levels, inter- and intra subject 
variations. 
• Enable easy termination of the medications, when needed. 
• Can be applied to a relatively large area for application of drugs in comparison 
with buccal or nasal cavity. 
• Are suitable for self-medication. 
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1.2.2 Disadvantages of Topical Drug Delivery Systems 
These dosage forms may: 
• Cause skin irritations leading to contact dermatitis due to the use of the drug 
and/or excipients. 
• Cause poor permeation of some drugs through the skin because of the 
complexity of the skin tissue.  
• Be less effective for systemic delivery.  
• Be used for systemic effect only when very small plasma concentration of drug is 
required for action. 
• Be denatured by the skin enzymes present mainly in the epidermis.  
• May not be absorbed easily through the skin if the size of drug particles is large.   
 
1.3 Factors Affecting the Absorption of Drugs through Skin 
The physicochemical properties of the drug and topical dosage form formulated 
play major roles in affecting the rate and extent of drug absorption by the skin. 
Moreover, the physiological conditions of the skin most probably affect the drug 
transportation to the systemic circulation (Wiechers, 1989). Some of these factors are 
also mentioned in Section 1.3.3. 
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1.3.1 Physicochemical Properties of Drug Substances 
The physicochemical properties of the topical administered drugs are:  
• Partition coefficient: Ideally, the partition coefficient into octanol-water system 
should be between 1 to 4 for a successful topical drug delivery (Naik et al., 
2000). 
• Drug solubility: The higher the solubility of the drug is in the vehicle, the greater 
is the permeation of the drug through the skin. 
• Concentration: When the drug concentration in the vehicle is above the saturated 
level, then there would be an increase in the permeability of the drug. The 
mechanism of enhancement via drug supersaturation would therefore be based 
simply on the increased thermodynamic activity of the drug in the vehicle, i.e. an 
increased driving force for its transition out of the formulation into and across the 
stratum corneum. However, the major limitation of this technique is that once the 
drug concentration is increased, then the supersaturated formulations are 
typically subject to recrystallization of the drug substance (Williams, 2003). 
•  Particle size: The smaller the particle size is, the greater is the surface area and 
the permeation of the drug through the skin. In this regard, the nano and micro-
emulsion systems are of prime interest. 
• Polymorphism: The most soluble polymorph of the drug should be chosen for the 
preparation of the formulation as it would affect the permeability through the 
skin. 
• Molecular weight: A drug with a molecular weight less than 400 dalton would 
easily permeate through the skin tissues (Naik et al., 2000). 
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1.3.2 Release Properties of Topical Drug Delivery 
  If drug molecules present in the internal phase of emulsion system, then the drug 
needs to be partitioned from the internal phase to the external phase first before being 
absorbed by the skin. It is important for the release from the dosage form to be rapid if a 
fast absorption and effect are needed. The release of drug from a dosage form may be 
affected by the composition of drug delivery system. Some of the excipients in the 
formulation may enhance the absorption and some may retard the absorption of the 
drugs. For example, propylene glycol of low molecular weight may reduce permeation 
and absorption of drug while polyethylene glycols may cause the opposite effect. 
 
1.3.3 Physiological and Pathological Conditions of Skin 
The physiological and pathological properties of the skin which could affect the drug 
permeation are: 
• Effect of horny Reservoir layer: The horny layer of the skin may bind with drug 
molecules and act as a depot for the drug in therapy.  
• Lipid film: The lipid film formed naturally on the skin surface would act as a  
protective layer  to prevent moisture loss from the skin. 
• Skin hydration: Hydration of the stratum corneum by an occlusive cover applied 
over it would prevent moisture loss from the skin and would enhance the 
absorption of drugs.  
• Skin temperature: When there is an increase in body temperature, it results in an 
increase in the rate of skin permeation. This may be due to an increased thermal 
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energy which may enhance drug diffusion, and may increase the solubility of the 
drug in skin tissues at higher temperature as well as the vasodilation of the blood 
vessels. 
• Regional variation: The difference in the nature and thickness of the skin in 
different parts of the body would lead to the difference in permeability to drugs. 
The rate of permeation increases in an anatomic order: Plantar anterior fore arm, 
scalp, ventral thigh, scrotum and posterior auricular area. 
• Pathologic injuries of the skin: When there is an injury to the skin, in particular 
to the stratum corneum, there would be an increase in permeability.  
• Cutaneous drug metabolism: The metabolising enzymes present in the viable 
epidermis may metabolise the drug to an inactive metabolite before reaching the 
circulation. This would lead to a reduced topical bioavailability and decreased 
pharmacodynamic activity of the drug. For example, Testosterone is 95% 
metabolised in the viable epidermis layer (Hadgraft, 2001). 
 
1.4 Penetration Enhancement 
Barrier function of the skin would normally not allow most of the foreign molecules 
including drugs to penetrate into the skin. Therefore, different approaches have been 
proposed by various researchers to enhance the penetration of the drug molecules 
through the skin (Thomas and Finnin, 2004). The enhancement of drugs permeation 
through the skin can be achieved either by chemical enhancers or by physical methods.  
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1.4.1 Chemical Penetration Enhancers
A chemical skin penetration enhancer increases skin permeation by reversibly 
altering or damaging the nature of the stratum corneum. The alteration includes 
increased hydration of stratum corneum and/or a change in the lipid and lipoprotein 
structure.  The various chemical penetration enhancers are:  
Solvents: These solvents enhance the permeation process possibly by swelling the  
polar pathway through the stratum corneum and/or by fluidizing the lipids of the 
membrane. Examples of these solvents include water, alcohol, methanol ethanol, 
propylene glycol, glycerol isopropyl palmitate.  
• Surfactants: These compounds are proposed to enhance the permeation by 
reversibly affecting or damaging the strateum corneum. The commonly used 
surfactants are: 
i. Anionic surfactants: They are strong permeation enhancer but they 
are irritants to the skin. They may even interact strongly with the skin. 
Examples include dioctyl sulpho succinate, sodium lauryl sulphate 
etc.  
ii. Cationic surfactants: These surfactants are reported to be more 
irritating to the skin. So, they are very rarely used for permeation 
enhancement.  
iii. Nonionic surfactants: These are the surfactants with least potential of 
causing skin irritation. Examples are Tweens and Spans etc. which 
are widely used in topical delivery prepartions (Black, 1993).  
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1.4.2 Physical Methods for Enhancing Topical Drug Delivery 
The physical techniques that can enhance drug permeation are as follow: 
• Iontophoresis: Iontophoresis is a technique that is used to transport ionic or 
charged molecules into a skin tissue through a passage of an electrolyte solution 
containing  ionic molecules that will be delivered by using an electric current of 
appropriate polarity (Prausnitz et al., 1996). 
• Electroporation: This method involves an application of transient high voltage 
electrical pulse (250 v) to cause rapid dissociation of the stratum corneum. The 
rapid dissociation involves structural and conductance changes in the cell 
membranes thereby increasing the pore size for enhanced absorption (Prausnitz 
et al., 1996). 
• Sonophoresis: This method involves the usage of ultrasound waves of low  
frequency (25 kHz).  
• Phonophoresis: In this technique, an ultrasound-coupling agent is placed over 
the area on the skin to be treated. The area of skin is  then massaged  with an 
ultrasound source. The movement of drugs through skin under the ultrasound 
perturbation is known as phonophoresis.  
• Vesicular Concept: The various vesicles used for this purpose are liposomes, 
niosomes and transferosome. These vesicles can enhance the permeability of the 
drug by reversibly altering the cell membranes. 
• Microfabricated Microneedles Technology: In this technique, drug loaded in 
silicon microneedles are used.  After the introduction into the skin, these 
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microneedles will create conduits for the transfer of the drug through the stratum 
corneum. Once the drug passes the stratum corneum, it rapidly diffuses further 
and enters the systemic circulation (Prausnitz, 2004, Teo et al., 2006). 
1.5 Semisolid Topical Drug Delivery Systems 
The two main semi solid dosage forms of topical medication are cream and 
ointment. The ointment is a topical delivery system where the drug is dissolved in a 
lipophilic vehicle, such as liquid paraffin. The ointment is a water-free system. 
Inversely, cream is a water-containing system with the presence of oil and surfactant or 
emulsifier. It can be classified as water in oil (W/O) cream when the oil constitutes the 
external phase and oil in water (O/W) when the water is the external phase. Therefore, 
creams can be defined as O/W or W/O emulsion that have a colloidal gel structure 
(junginger, 1994). Emulsion, micro-emulsion and nano-emulsion systems are considered 
as an efficient carrier for many drugs to be delivered topically (Williams, 2007). 
 
1.5.1 Emulsion 
Emulsion is a mixture of two immiscible liquids. One will act as the external or 
continuous phase, while the other is dispersed in droplet forms. The mixture is stabilized 
by the addition of emulsifying agent which maintains the dispersion of the immiscible 
liquids. The dispersed phase droplets’ sizes range between 0.1 to 10 mm. Despite its 
instability problems, emulsion has been used extensively to improve the solubility, 
absorption and bioavailability of poorly water soluble drugs (Eccleston, 2007). 
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1.5.2 Micro-Emulsions 
Micro-emulsion is a system formed spontaneously without an extensive mechanical 
input. The size of the dispersed phase droplets ranges between 15 - 200 nm (Kwon and 
Bourne, 1997, Esposito et al., 2003, Cai et al., 2007). It is thermodynamically stable 
since the spontaneous formation process happens without a high energy input during the 
mixing process. The free energy of the micro-emulsion system is equal to (γ A) where A 
is the total of new interfacial area formed after the formation of the emulsion and γ is the 
interfacial tension of the system. A is high but γ is near to zero since the surfactant 
should reduce efficiently the interfacial tension, thereby making the free energy of the 
system  almost to zero. Usually, single surfactant cannot reduce the interfacial tension to 
the extent that the system can be formed spontaneously (Moulik and Paul, 1998). Thus, 
there is a need for the addition of second surfactant or co-surfactant. 
Double alkyl chain surfactant and some non-ionic surfactants were found to be able 
to produce this emulsion system (Biruss and Valenta, 2008). The addition of another 
surfactant or co-surfactant can reduce the interfacial tension so as to be of negative 
value. The surfactant mixture or surfactant with co-surfactant can work synergistically in 
reducing the interfacial tension through the formation of a mixed layer at the interface.  
In general, there are three main structures that can be accounted for the micro-
emulsion system. These are the O/W (where oil micro-droplets are dispersed in the 
water external phase), the W/O (where water micro-droplets are dispersed in the oil 
external phase) and the bi-continuous micro-emulsion (where the water and oil phase are 
presented as a continuous phases separated by a surfactants rich interfacial layer) 
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(Moulik and Paul, 1998). Bi-continuous micro-emulsion is usually related with the 
system containing an equal amount of oil and water. Surfactant is the essential factor for 
determining the type of micro-emulsion. Viscous micro-emulsion can be produced 
through the usage of particular surfactants. The use of nonionic surfactant mixture 
results in the formation of viscous micro-emulsion with a gel structure.  A combination 
of many structures was found to have been formed in micro-emulsion system. These 
systems include combination of hexagonal and cubic crystalline liquid structures which 
are formed in the micro-emulsion produced (Carlfors et al., 1991, Bolzinger et al., 
1998). Nonionic O/W micro-emulsion can form a highly viscous gel structure through 
the formation of a network between the H-bonds of the polyoxyethylene chain of the 
surfactants surrounding the oil droplets (Podlogara et al., 2004). Lecithin can  form a 
highly viscous W/O micro-emulsion system through the formation of a worm like 
micelles, where the oriented chains from each micelle will attach the chain of the other 
micelle to form a network (Paolino et al., 2002). 
 
1.5.3 Nano-Emulsion 
Nano-emulsion is another emulsion system comprising of two immiscible liquids in 
which one liquid is dispersed as fine droplets in another liquid . It differs significantly 
from the conventional emulsion in its droplets size which range between 20-200 nm in 
diameter. For its production, energy input is necessary espacially when the concetration 
of surfactant is not very high. Although the formed dispersion is thermodynamically 
unstable, it is kinetically stable due to the very small particle size that reduces the 
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sedimentation or creaming of the dispersed droplets (Solans et al., 2005). O/W nano-
emulsions have been extensively studied  and  widely used for the parenteral and topical 
application (Benita and Levy, 1993).  It is suitable for the topical delivery of lipophilic 
drugs where the lipophilic drugs are dissolved in the inner oil phase (Sonneville-Aubrun 
et al., 2004). W/O nano-emulsion on the other hand has only been mentioned in 
publication recently (Gutiérrez et al., 2008). 
 The high energy method and the low energy method are the main techniques used 
in the preparation of nano-emulsion. The high energy method includes the input of high 
energy for the emulsification of the system in order to produce nano sized dispersion 
droplets . Either sonication or high pressure homogenization is used to provide  a high 
energy that is sufficient enough to transform and break up the internal phase of the 
system into droplets of submicron in size (Kentish et al., 2008, Yuan et al., 2008). The 
phase inversion method is a low energy technique where the external phase is added 
gradually to inverse the system to nano sized dispersion (Maestro et al., 2008). In 
another low energy technique, i.e. the temperature inversion method,the temperature is 
initially raised and then reduced to change the hydrophilic nature of the surfactant that 
results in a nano dispersion system (Solans et al., 2005).  
Although the nano-emulsion system is kinetically  stable, this system can be 
destabilized by subjecting it to the flocculation and Ostwald ripening phenomenon. The 
energy conserved within the system is the main cause for the degradation of the product 
(Akabori et al., 1978). 
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Micro-emulsion and nano-emulsion have many advantages to be used as topical 
drug delivery system.  The high solubilization of different compounds into this dosage 
form, the synergistic effect of various components to enhance drug delivery, as well as 
the small droplet size are the driving forces which had contributed to the high interest 
and active investigation of these topical drug delivery systems. The main ingredients; 
oil, water and surfactant mixture or surfactant, co-surfactant mixture can combine 
synergistically to enhance the drug flux (Kreilgaard, 2002).  
 
1.5.3.a Oils Used as Enhancers of Nano-Emulsion Topical Delivery Systems 
Fatty acids (such as oleic acid and isopropyl esters like isopropyl myristate) present 
in the micro and nano-emulsion are topical enhancer oils that have been studied 
extensively. Oleic is an unsaturated C18 alkyl chain which has cis-configuration. It was 
found that oleic acid has the ability to raise 5 fluorouracil flux through the human skin 
by 56 folds (Goodman and Barry, 1989). Oleic acid was also detected to improve the 
topical absorption of amino acid and naloxane efficiently (Aungst et al., 1986). 
Similarly, isopropyl myristate has been mentioned as a considerable permeation 
enhancer for topical delivery of steroids (Peltola et al., 2003, Djordjevic et al., 2004).   
Ester wax is an oil phase used in the preparation of creams and ointments. Ester wax 
is found naturally in the jojoba oil. This type of oil has unique properties of high 
physical stability and in the reduction of emulsion droplet size (Chung et al., 2001). It 
has a protective and occlusive effect on the skin which in turn can hydrate the skin and 
increase permeability through the skin (Lautenschläger, 2003). The use of jojoba oil in 
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the formulation of lipogel was discovered to improve fluconazole flux by 1.5 folds as 
compared to the use of cutina oil (Kreilgaard, 2002). 
 
1.5.3.b Aqueous Phase in Nano-Emulsion Topical Delivery Systems  
Water as well as phosphate buffer pH 7.4 were mainly incorporated as the aqueous 
phase of topical delivery micro-emulsion system by various researchers (Alvarez-
Figueroa and Blanco-Méndez, 2001, Trotta et al., 2003). The absorption of water leads 
to the hydration of the stratum corneum that enhances drug permeation through the 
loosening of the tightly lipid lamellae (Walters and Roberts, 1993). 
 
1.5.3.c Surfactants Used in Topical Delivery Systems 
Ionic surfactant and non-ionic surfactant can disturb the lipid bilayer of the stratum 
corneum thereby making it a less effective barrier to the permeation of the drug. Ionic 
surfactant however, was found to induce irreversible changes in the structure of the 
stratum corneum lipid bilayer, hence it is not preferable for use in the topical delivery. In 
contrast, non-ionic surfactants are widely and safely used for the topical delivery system. 
Different skin species and different drug models respond differently to the enhancing 
effect of non-ionic surfactant (Black, 1993, Williams, 2003, Masayuki et al., 1996). 
Listed in Table 1.1 are some of the researchers carried out on micro-emulsion using 
different combination of drug, oil phase, surfactant system, aqueous phase and 
membrane model. 
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1.5.4 Techniques Used in the Structural Characterization of the Nano- and Micro- 
Emulsion Systems 
The identification of micro- and nano-emulsion system structures can be carried out 
by using various instruments like Scanning Electron Microscopy, TEM (Transmission 
Electron Microscopy) (Danino et al., 2002), SAXS (Small Angle X-ray Scattering) 
(Glatter et al., 2001) and SANS (Small Angle Neutron Scattering) (Silas and Kaler, 
2001). Scanning electron microscopy and TEM are electron microscopy instruments 
which make use of the beam of highly condensed and monochromic electrons to identify 
the size, shape, surface feature and structure of the samples. Viscosity and conductivity 
measurement can also indicate the structure of these systems (Djordjevic et al., 2004). 
 
Table 1.1: Overview of micro-emulsion formulations reported by various 
researchers. 
Micro-emulsion 
Drug 
Oil phase Surfactant/ co-surfactant Water 
Membran
e/ skin 
[3H] H2O Octanol 
dioctyl sodium 
sulphosuccinate Water Human 
5-Fluorouracil Isopropyl myristate 
Octadecyltrimethylammoni-
um bromide Water Mouse 
8-Methoxsalen Isopropyl myristate 
Tween 80®, Span 80®, 1,2-
octanediol Water Pig 
Apomorphine 
hydrochloride 
Isopropyl 
myristate, 
decanol 
Epikuron 200®, 1, 2-
propanediol benzyl alcohol 
Water, 
Aerosil 
200®
Mouse 
Ascorbic acid 
Isopropyl 
palmitate,      
cetearyl 
octanoate 
Dodecylglucoside 
cocoamide propylbetaine, 
phosphatidylcholine/2-
ethyl-1,3-hexanediol 
Water - 
Ascorbyl 
palmitate Mygliol 812
® Labrasol®/Plurol Oleique® Water - 
Diclofenac Isopropyl palmitate Lecithin Water Human 
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Continued of Table 1.1 
Felodipine 
Isopropyl 
myristate, 
benzyl alcohol 
Tween 20, 
Taurodeoxycholate 
Water, 
Transcut-
ol, 
carbopol 
Mouse 
Glucose Octanol Dioctyl sodium, sulphosuccinate Water Human 
Hematoporphyr-
in 
Isopropyl 
myristate, 
decanol, 
hexadecanol, 
oleic acid, 
monoolein 
Lecithine, 
monohexylphosphate 
,benzyl alcohol 
Water Mouse 
Indomethacin Isopropyl palmitate Lecithin Water Human 
Ketoprofen 
 
Oliec acid, 
Triacetin, 
MYvacet 
Labrasol, Cremophor, RH Water Rat 
Lidocaine 
 
Isostearylic 
isostearate 
Labrasol, Plurol, 
Isostearique Water Rat 
Methotrexate 
 Decano 
Lecithin, benzyl alcohol, 
Labrasol / Plurol 
Water, 
PG Mouse 
Methotrexate Ethyl oleate Isostearique 
Aq. 145 
mM NaCl 
(pH 7.4) 
Pig 
Methotrexate Isopropyl myristate 
Tween 80, Span 80, 1,2-
octanediol Water Pig 
Nifedipine Benzyl alcohol Tween 20, taurodeoxycholate 
Water, 
Transcuto
l, PG 
Mouse 
Prilocaine  
hydrochloride Isostearate 
Labrasol, Plurol, 
Isostearique water Rat 
Propanolol Isopropyl myristate Polysorbate 80 Water Artificial 
Prostaglandin E Oleic acid Labrasol, Plurol, Oleique Water Mouse 
Prostaglandin E Gelucire Labrafac, Lauroglycol Transcutol, Water Mouse 
Sodium 
salicylate 
Isopropyl 
myristate 
Tween 21/81/ 85, bis- 2-
(ethylhexyl) 
sulphosuccinate 
Water, 
gelatin Pig 
Sucrose Ethyl oleate Labrasol, Plurol,  Isostearique 
Aq. 154 
mM NaCl Mouse 
*This table is adapted from  (Kreilgaard, 2002) 
 
1.5.5 Properties of Semisolid Topical Delivery System 
The topical preparation containing drugs must have special rheological properties. 
The preparation must stick to the skin when it is applied to ensure drug delivery at the 
site of application. This means that the topical preparation must be as a solid form under 
rest condition as well as in the liquid form under stress condition when the mechanical 
force is applied to remove the dose from the container. Hence, the name semi-solid 
preparation was introduced to describe these unique dosage forms. Semi-solid 
preparation is defined as a gel structure preparation containing a drug for topical 
delivery. A gel structure is formed by the formation of a solid network in which a liquid 
is incorporated to form a sponge-like structure. The gel form does not flow when the 
force applied is lower than the elastic strength of the network but will flow at certain 
viscosity when the applied force exceeded the elastic strength. This unique rheological 
flow is known as viscoelastic or plastic flow (Barry and Meyer, 1973). 
 
1.6 The Main Ingredients Selected in This Study: 
1.6.1 Piroxicam 
SNO
NH
O
O
N
HO
(4-hydroxy-2-methyl-N-(2-pyridyl)- 2H- 1,2-benzothiazine- 3- carboxamide- 1,1 -dioxide)  
Fig. 1.1: Chemical Structure of piroxicam. 
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1.6.1.a Physicochemical Properties 
Piroxicam  is a crystalline powder, off-white to light yellow in colour with a bitter 
taste (USP 27, 2003). Piroxicam can be crystallized from an ethanolic solution through a 
fast cooling technique to form a needle shaped crystal. On the other hand, the 
crystallization of the ethanolic solution through the slow cooling technique will result in 
the formation of cubic crystals. Piroxicam is neither soluble in water nor in cyclohexane. 
It is sparingly soluble in diisopropyl ether and slightly soluble in ethanol and 
isopropanol solvent. It is soluble in some polar organic solvents like dimethyl 
formamide, dimethyl sulfoxide and chloroform and to a less extent in dioxane, 
acetonitrile and acetone. This drug is a weak acid compound with a pKa value of 5.3 and 
its partition coefficient (Log P octanol/phosphate buffer pH 7.4)  is 1.8 (Mihalic, 1986).  
 
1.6.1.b Pharmacodynamics 
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) which shows its anti-
inflammatory and analgesic activity through a non selective inhibition of 
cyclooxygenase-1 (COX1) and cyclooxygenase-2 (COX2) receptors. 
 
1.6.1.c Pharmacokinetic Properties 
The group of enolic acid NSAIDs has a long half life. As for piroxicam, it is 50 
hr. Hence, the steady state blood concentration is achieved after 7-12 days after 
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oral administration. The plasma protein binding is as high as 99%. Piroxicam 
metabolism is mainly accomplished in the liver through hydroxylation and 
conjugation with glucouronic acid. It is excreted through the urine with 5% of 
the excreted drug remaining unchanged. It has been reported that there is a 
presence of piroxicam in the breast milk of mother who take piroxicam orally. 
Piroxicam is well absorbed from the GIT and the plasma peak level is achieved 
after a duration of between 3-5 hr (Martindale, 2002). On the other hand, 
Betadex a modified tablet form containing piroxicam and β cyclodextrine has the 
ability to reach the peak plasma level for piroxicam within 30-60 minutes. 
Topically, Piroxicam is absorbed from gel through the skin slowly but 
incompletely. The peak plasma level is reached only after 4 days of the 
application of piroxicam gel twice a day (Marks and Dykes, 1994)  
 
1.6.1.d  Dosage and Administration 
Piroxicam is available in the market in the form of 10 mg and 20 mg capsules to be 
taken as a single dose daily.  Piroxicam Betadex is offered as a 191 mg of a mixture of 
piroxicam with β cyclodextrine containing 20 mg of piroxicam that is to be given once 
daily (BNF 47, 2004). Sublingual tablet of 20 mg is affordable by everyone in the 
market. Piroxicam is also available as 0.5% gel for topical application. Suppositories 
containing 20 mg or 10 mg of piroxicam are available in the market too. Besides, a 20 
mg/ml intramuscular injection is also available in the market. 
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1.6.2 Oil 
Palm oil esters (POEs) is constituent of a modified form of Palm olein oil known 
simply as palm oil. A main and important agriculture commodity of which received 
great attention from researchers especially Malaysian researchers. Structurally, palm oil 
is a mixture of triglyceride compound. Palm oil is an edibile oil and is used through out 
the world as main ingredient in many food products. Palm oil, as a raw material, had 
also attracted many researchers to study its use in topical delivery products and in the 
effort to synthesize new derivatives with beneficial properties for chemical and 
pharmaceutical applications. Universiti Putra Malaysia (UPM) had led the way  in the 
production of new derivatives of palm oil (Keng et al., 2005). Palm oil had been 
discovered to react with oleyl alcohol and the reaction was catalysed by the use of lipase 
enzyme to produce POEs contained high molecular weight esters of alcohol with an 
even number of carbon ranging from 12-32 (Keng et al., 2008). The composition of 
POEs and its physical properties are represented below in Table1.2 and Table 1.3 
respectively.  
It was found that POEs has skin hydration activity of 40.7% after 90 minutes of its 
application (Keng. et al., 2009). The emollient effect of POEs had been proven thereby 
making this oil highly recommendable for its incorporation into the topical preparation 
as oil phase.  
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Table 1.2: Chemical Composition of Palm oil Eesters (Keng et al., 2008).  
Esters  Composition (%) 
Oleyl laurate 0.71- 0.97 
Oleyl myristate 3.2- 4.4 
Oleyl palmitate 31.1- 39.9 
Oleyl stearate 4.2- 4.7 
Oleyl oleate 31.4- 35.3 
Oleyl linoleate 6.4- 7.1 
 
 
Table 1.3: Physicochemical Properties of POEs (Keng et al., 2008).  
Properties Result 
Physical state Liquid 
Appearance Clear yellow 
Solubility in water Insoluble 
Iodine value 76.59 
Cloud Point(°C) 19.07 
Viscosity (cP) 19.73 
Density (g/cm³) 0.85 
 
 
 
 
 
1.6.3 Surfactants 
Non-ionic surfactants are widely used in topical preparation. These surfactants are 
compatible with acidic and basic media and less liable to hydrolysis and degradation by 
micro-organism (Idson, 1988). These surfactants are non-toxic surfactants and can be 
used safely for the topical delivery. It is reported that the recommended dose of Tween 
and Span are 25 mg/kg for human body per day (Raymond et al., 2003).   
Tween 80 is a non-ionic surfactant that is widely used as an emulsifier in the 
preparation of emulsion for cosmetics and topical applications. Structurally, it consists 
of four polyoxyethylene chains containing 20 carbons attached to sorbitan monooleate. 
The polyoxyethylene chains are responsible for the hydrophilicity of this surfactant 
thereby making it  a water soluble surfactant with HLB value of 15. It is a yellowish 
viscous liquid.  According to researchers, 80 is the number related to the oleate group 
which represents the hydrophobic part of the surfactant. 
 
 
Fig. 1.2: Chemical Structure of Tween 80. 
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 Similarly, Tween 85 consists of four polyoxyethylene chains containing 20 carbons. 
In fact, 85 is the number related to the tri-oleate chains that represent the hydrophobic 
part of the surfactant. Tween 85 is water soluble and is an amber coloured liquid 
surfactant with HLB value of 11.  
 
 
Fig. 1.3: Chemical Structure of Tween 85. 
 
Span 20 and Span 85 are lipophilic non-ionic surfactants wich have emulsifying and 
solubilizing effects. They are esterified forms of sorbitol and are termed as sorbitan 
esters. Span 20 is a monolaurate ester of sorbitan. It is a viscous liquid which is yellow 
in colour with the viscosity value of 3900-4900 mPa at C. The HLB value of 
sorbitan Monolaurate is 8.6. It is widely used in the formulations used for topical 
delivery. Span 85 is a trioleate ester form of sorbitan. It is an amber viscous liquid with a 
viscosity value of 200-250 mpa at 25 °C. It posses HLB value of 1.6. 
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Fig. 1.4: Chemical Structure of  Span 20. 
 
 
Fig. 1.5: Chemical Structure of  Span 85. 
 
1.7 Literature Review of Piroxicam Topical Drug Delivery 
Piroxicam is a water insoluble drug with an acidic pKa value of 5.3. Structurally, 
the pyridine ring that is attached to the amide group also provides a pKa value of 1.86. 
Therefore, it is possible that piroxicam can act as a zwitter ionic drug at certain pH 
value. As a weak acid, piroxicam ionizes at pH 7.4 and at physiological pH (Jinno et al., 
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